Clinical Trial Update: Zanubrutinib in Primary Cold Agglutinin Disease [Phase 2]

View source ↗

Summary

Phase 2 trial of zanubrutinib for primary cold agglutinin disease is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cold Agglutinin Disease

Drugs mentioned

• Zanubrutinib (zanubrutinib)

Snippet

Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland | Conditions: Lymphoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING